These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 17020565)
1. Overview of pharmacology and clinical trials program with the zotarolimus-eluting endeavor stent. Kandzari DE; Leon MB J Interv Cardiol; 2006 Oct; 19(5):405-13. PubMed ID: 17020565 [TBL] [Abstract][Full Text] [Related]
2. Zotarolimus-eluting stents in patients with native coronary artery disease: clinical and angiographic outcomes in 1,317 patients. Gershlick A; Kandzari DE; Leon MB; Wijns W; Meredith IT; Fajadet J; Popma JJ; Fitzgerald PJ; Kuntz RE; Am J Cardiol; 2007 Oct; 100(8B):45M-55M. PubMed ID: 17950832 [TBL] [Abstract][Full Text] [Related]
3. Development and performance of the zotarolimus-eluting Endeavor coronary stent. Kandzari DE Expert Rev Med Devices; 2010 Jul; 7(4):449-59. PubMed ID: 20583882 [TBL] [Abstract][Full Text] [Related]
4. ABT-578-eluting stents. The promising successor of sirolimus- and paclitaxel-eluting stent concepts? Buellesfeld L; Grube E Herz; 2004 Mar; 29(2):167-70. PubMed ID: 15054589 [TBL] [Abstract][Full Text] [Related]
10. The relation between clinical features, angiographic findings, and the target lesion revascularization rate in patients receiving the endeavor zotarolimus-eluting stent for treatment of native coronary artery disease: an analysis of ENDEAVOR I, ENDEAVOR II, ENDEAVOR II Continued Access Registry, and ENDEAVOR III. Mehta RH; Leon MB; Sketch MH; Am J Cardiol; 2007 Oct; 100(8B):62M-70M. PubMed ID: 17950834 [TBL] [Abstract][Full Text] [Related]
11. XIENCE V everolimus-eluting coronary stent system: a novel second generation drug-eluting stent. Beijk MA; Piek JJ Expert Rev Med Devices; 2007 Jan; 4(1):11-21. PubMed ID: 17187467 [TBL] [Abstract][Full Text] [Related]
14. Drug-eluting coronary stents: many meta-analyses, little benefit. Prescrire Int; 2009 Apr; 18(100):70-4. PubMed ID: 19585727 [TBL] [Abstract][Full Text] [Related]
15. Is there a preferable DES in diabetic patients? A critical appraisal of the evidence. Byrne RA; Kastrati A Catheter Cardiovasc Interv; 2008 Dec; 72(7):944-9. PubMed ID: 19021280 [TBL] [Abstract][Full Text] [Related]
16. A randomized comparison of sirolimus-eluting stent implantation with zotarolimus-eluting stent implantation for the treatment of total coronary occlusions: rationale and design of the PRImary Stenting of Occluded Native coronary arteries III (PRISON III) study. Suttorp MJ; Laarman GJ; Am Heart J; 2007 Sep; 154(3):432-5. PubMed ID: 17719285 [TBL] [Abstract][Full Text] [Related]
17. Four-year clinical follow-up after implantation of the endeavor zotarolimus-eluting stent: ENDEAVOR I, the first-in-human study. Meredith IT; Ormiston J; Whitbourn R; Kay IP; Muller D; Popma JJ; Cutlip DE; Fitzgerald PJ; Am J Cardiol; 2007 Oct; 100(8B):56M-61M. PubMed ID: 17950833 [TBL] [Abstract][Full Text] [Related]
18. 5-year clinical outcomes after sirolimus-eluting stent implantation insights from a patient-level pooled analysis of 4 randomized trials comparing sirolimus-eluting stents with bare-metal stents. Caixeta A; Leon MB; Lansky AJ; Nikolsky E; Aoki J; Moses JW; Schofer J; Morice MC; Schampaert E; Kirtane AJ; Popma JJ; Parise H; Fahy M; Mehran R J Am Coll Cardiol; 2009 Sep; 54(10):894-902. PubMed ID: 19712798 [TBL] [Abstract][Full Text] [Related]
19. Understanding the drug-eluting stent trials. Coolong A; Kuntz RE Am J Cardiol; 2007 Sep; 100(5A):17K-24K. PubMed ID: 17719349 [TBL] [Abstract][Full Text] [Related]
20. Sirolimus-eluting cobalt-chromium stents: two-year clinical results from first-in-man study on the Firebird 2 stent. Xu B; Zhang Q; Yang YJ; Qiao SB; Zhang RY; Zhang JS; Hu J; Qin XW; Hong T; Li JP; Chen JL; Huo Y; Gao RL; Shen WF Chin Med J (Engl); 2008 Mar; 121(6):492-7. PubMed ID: 18364131 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]